Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.

Lu GaoLi YangShiyuan ZhouWenjuan ZhuYue HanSuning ChenShengli XueYing WangHuiying QiuDepei WuXiao-Jin Wu

Published in: Stem cell research & therapy (2024)

The choice of donor type did not significantly affect the outcomes of allo-HSCT. However, when considering the quality of post-transplant life, MUDs or HIDs from younger donors may be the optimal choice for elderly patients.

Keyphrases

acute myeloid leukemia
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
type diabetes
decision making
patient reported outcomes
quality improvement
acute lymphoblastic leukemia
weight loss